利特昔替尼的正确购买途径

Introduction: Literitinib is a highly selective Janus kinase 3 (JAK3) inhibitor. In June 2023, the drug was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above. Riterlitinib's dual activity against the JAK3 and TEC kinase families blocks cytokine signaling as well as the cytolytic activity of T cells, both of which are implicated in the pathogenesis of alopecia areata.

The correct way to purchase generic drugs of ritexitinib

Currently, generic drugs have not been launched in China and cannot be purchased directly in China. Here are some suggestions.

1. Overseas hospitals: Patients can go to hospitals in Laos and purchase generic ritexitinib directly in the hospital pharmacy after a professional doctor issues a prescription.

2. Overseas pharmacies: Patients can purchase it in local pharmacies in countries where generic ritexitinib is on the market, such as Lucius’s generic version of ritexitinib in Laos.

3. Medical service institutions: Patients can also obtain medicines through the help of domestic professional overseas medical service institutions. They can have medicines mailed to their homes. This method may be more cost-effective and can save a certain amount of financial expenditure.

Please note that when purchasing and using ritexitinib, you should strictly abide by the doctor's prescription and medication instructions to ensure medication safety. At the same time, since drug prices and purchasing channels may change over time, it is recommended to consult the latest information before purchasing.

The price of ritixitinib

The price of ritixitinib may vary depending on the region, drug version, and sales channel. The winning bid price for a box of 50mg*30 tablets of ritexitinib is $2,800 per box. In addition, the Laos Lucius version of ritexitinib is a generic drug, its specification is 50mg*28 tablets, and the reference price is about 1200$-1700$ per box.

It will be affected by many factors, including region, drug version, purchasing channel, etc. Therefore, it is recommended to consult a doctor or pharmacist to understand the actual local price before purchasing.

Ritexitinib is hepatotoxic

In premarketing clinical trials for alopecia areata, serum aminotransferase elevations were seen in 1%-3% of subjects treated with ritexitinib, but similar increases were seen in subjects treated with placebo. Elevations are usually mild and transient, and less than 1% of patients have elevations greater than 5 times the upper limit of normal (ULN). Elevations rarely lead to premature discontinuation and usually resolve without dose adjustment.

In premarketing studies in alopecia areata and other autoimmune diseases, there were no cases of liver-related serious adverse events or clinically apparent liver injury associated with ritexitinib. Since the approval and wider use of ritrectinib, no reports of hepatotoxicity related to its use have been published.